NEW YORK, April 26, 2016 /PRNewswire/ -- Diabetes has exhibited dramatic increases during the past decade, registering a global prevalence of 9% among adults aged 18 years and older, and is projected to be the 7th-leading cause of death by 2030. The most popular treatment for type 1 diabetes mellitus (T1DM) is multiple daily insulin (MDI) injections. However, researchers globally are working on both the development of novel drugs to fight diabetes, and on the design of novel insulin delivery systems.
These delivery systems mostly via use oral and pulmonary routes using nanocarrier-based delivery systems, as well as transdermal delivery to through patches and infusion pumps, which aim to improve the quality of life of diabetic patients. An important new business model is emerging between large pharmaceutical/biopharmaceutical companies and medical devices firms with the objective of accelerating the delivery of novel therapeutic systems to the industry.
Medical device companies and drug manufacturing companies sign long-term partnership agreements to combine their drug delivery devices with the most-active diabetes therapeutics, thereby bringing down the operational costs and saving a significant amount of time during the process.
This research service (RS) examines the current landscape and new trends in diabetes drug delivery, focusing on: Technology trends and capability Stakeholder activities, influence, industry initiatives, and applications targeted Industry initiatives, regulation, and standardization approaches for tackling challenges Technology benchmarking for specific applications An appendix is included, comprising lists of the major participants in the study and the most notable patents in the field.
Read the full report: http://www.reportlinker.com/p03758968-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001